Quotes 5-day view Delayed Nasdaq
10/13/2020
10/14/2020
10/15/2020
10/16/2020
10/19/2020
Date
123.75(c)
122.52(c)
122.03(c)
124.13(c)
121.76 Last
1 461 461
1 883 948
1 474 412
4 251 190
1 623 022 Volume
-0.51% -0.99% -0.40% +1.72% -1.91% Change
Sales 2020
5 753 M - -
Net income 2020
329 M - -
Net Debt 2020
77,6 M - -
P/E ratio 2020
84,2x
Yield 2020
-
Sales 2021
6 396 M - -
Net income 2021
2 153 M - -
Net cash position 2021
1 365 M - -
P/E ratio 2021
12,3x
Yield 2021
-
Capitalization
27 206 M 27 206 M -
EV / Sales 2020
4,74x
EV / Sales 2021
4,04x
Nbr of Employees
3 082
Free-Float
91,3%
Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers.
At the end of 2019, the group had a portfolio of 6 products in clinical development.
Net sales are distributed geographically as follows: the United States (55.6%), Europe (24.2%), Asia/Pacific (10.6%) and other (9.6%).
Notations Surperformance© of Alexion Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
All news about ALEXION PHARMACEUTICALS, INC.
News in other languages on ALEXION PHARMACEUTICALS, INC.
Chart ALEXION PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ALEXION PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
22
Average target price
145,32 $
Last Close Price
124,13 $
Spread / Highest target
41,0%
Spread / Average Target
17,1%
Spread / Lowest Target
-5,74%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
